Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.

about

Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials Investigational insulin secretagogues for type 2 diabetes.

P2860

Q36303980-E20FA2B8-75F8-4558-A887-44361022B6D9 Q38735419-F3FECEA6-8A06-4841-BB36-1E47ABF71117

P2860

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.

Item

http://www.wikidata.org/entity/Q38154623

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimizing glycemic control: l ...... t of Type 2 diabetes mellitus.

@en

type

Item

label

Optimizing glycemic control: l ...... t of Type 2 diabetes mellitus.

@en

prefLabel

Optimizing glycemic control: l ...... t of Type 2 diabetes mellitus.

@en

P1476

Optimizing glycemic control: l ...... t of Type 2 diabetes mellitus.

@en

P2093

Ronnie Aronson

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

The biology of incretin hormones.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

P304

603-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2013.842465

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258067188

http://www.w3.org/2001/XMLSchema#string

P698

24147558

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.

about

P2860

P2860

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921